-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $215

Benzinga·08/07/2026 14:11:30
Listen to the news
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers the price target from $225 to $215.